Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Aug 6 · below the Ichimoku cloud · RSI 36 · MACD below its signal
None of the 29 investors followed here reported a position in CELZ in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CELZ trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 23, 2026 | Warbington TimothyChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 1.00M | — |
| Feb 18, 2025 | Finger Michael H.Director | Sale at price 5.00 - 5.75 per share. | 1.5K | $8.06K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.1 | -10.4 | 13.8 | 9.2 | 0.0 | -35.6 | -54.2 | 70.2 | -17.3 | -12.3 | −58.2% | ||
| 2025 | 35.5 | 58.8 | -56.3 | -4.6 | 5.3 | 21.6 | 4.9 | 14.4 | 4.7 | -4.8 | -15.1 | -27.1 | −15.2% |
| 2024 | -8.2 | -1.7 | 25.2 | -14.8 | -2.0 | -11.5 | -9.9 | 0.3 | -10.9 | 33.6 | -35.6 | -13.3 | −49.9% |
| 2023 | 40.4 | 6.5 | -12.3 | 29.7 | -12.1 | -18.7 | 18.9 | -14.0 | 3.8 | -10.8 | 1.4 | 3.6 | +21.0% |
| 2022 | -7.2 | -11.2 | 114.3 | -51.8 | -51.0 | -18.6 | -1.3 | -5.7 | -37.0 | -2.3 | -4.7 | -7.0 | −82.8% |
| 2021 | -10.1 | 76.0 | -24.5 | 32.5 | -18.2 | -2.8 | -22.0 | -0.4 | -44.9 | -3.3 | -40.7 | -48.6 | −84.1% |
| 2020 | -33.3 | -61.7 | -60.9 | 55.6 | -44.3 | 20.5 | 14.9 | -37.0 | -14.7 | -34.5 | -15.8 | 1637.5 | −38.2% |
| 2019 | 11.1 | -7.3 | -1.0 | -18.8 | -32.9 | -29.1 | -38.5 | -45.8 | -38.5 | -50.0 | -25.0 | 0.0 | −97.0% |
| 2018 | -68.9 | -23.8 | 203.1 | 152.6 | -42.0 | 287.3 | -22.2 | -13.6 | -36.8 | -30.3 | -3.7 | -36.9 | −26.7% |
| 2017 | 0.0 | 0.0 | 0.0 | -11.8 | -10.0 | 11.1 | -6.7 | -47.6 | -9.1 | -10.0 | -77.8 | -66.3 | −97.4% |
| 2016 | 0.0 | 0.0 | 0.0 | 4445.5 | -40.0 | 10.0 | 0.0 | 54.5 | 0.0 | 0.0 | 0.0 | 0.0 | +4536.4% |
| 2015 | 0.0 | 0.0% |
Buy / hold / sell counts
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.